Trevi Therapeutics logo

Trevi TherapeuticsNASDAQ: TRVI

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 May 2019

Next earnings report:

20 March 2025

Last dividends:

N/A

Next dividends:

N/A
$212.92 M
-18%vs. 3y high
55%vs. sector
-vs. 3y high
-vs. sector
-69%vs. 3y high
73%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 21:02:26 GMT
$2.77-$0.27(-8.88%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

TRVI Latest News

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
prnewswire.com21 October 2024 Sentiment: POSITIVE

Topline results are expected in the first quarter of 2025 NEW HAVEN, Conn. , Oct. 21, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that it has completed enrollment in its Phase 2a trial for the treatment of RCC ("RIVER") and expects to report topline data in the first quarter of 2025.

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
prnewswire.com03 October 2024 Sentiment: POSITIVE

Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) chronic cough reaches 50% enrollment milestone; sample size re-estimation results expected in December 2024 Human Abuse Potential (HAP) study dosing complete; topline results expected in December 2024 NEW HAVEN, Conn. , Oct. 3, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today provided updates on its clinical development programs.

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.
prnewswire.com30 September 2024 Sentiment: POSITIVE

NEW HAVEN, Conn. , Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V.

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
prnewswire.com26 September 2024 Sentiment: POSITIVE

Professor Alyn Morice will present an analysis of cough relief in patients with idiopathic pulmonary fibrosis who were treated with nalbuphine ER NEW HAVEN, Conn. , Sept. 26, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2a CANAL trial will be presented at CHEST 2024 held in Boston, Massachusetts from October 6-9.

Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
marketbeat.com06 September 2024 Sentiment: POSITIVE

Publicly traded biopharmaceutical firms can have large, sometimes triple-bagger, expectations placed on them by Wall Street analysts. This is especially true for companies like Trevi Therapeutics NASDAQ: TRVI, which don't yet have any products approved by the Food and Drug Administration (FDA).

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024
prnewswire.com04 September 2024 Sentiment: POSITIVE

Professor Jacky Smith will present on the correlation between the change in objective cough count and improvement in patient-reported outcomes with nalbuphine ER in IPF patients NEW HAVEN, Conn. , Sept. 4, 2024  /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2a CANAL trial will be presented at the European Respiratory Society (ERS) Congress 2024 being held in Vienna, Austria from September 7-11.

Trevi Therapeutics to Participate in September Investor and Medical Conferences
prnewswire.com28 August 2024 Sentiment: POSITIVE

NEW HAVEN, Conn. , Aug. 28, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and medical conferences in September.

Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript
seekingalpha.com11 August 2024 Sentiment: NEUTRAL

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Jennifer Good - President and CEO Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Officer Conference Call Participants Thomas Smith - Leerink Partners Leland Gershell - Oppenheimer Mayank Mamtani - B. Riley Securities Brandon Folkes - Rodman & Renshaw John Gionco - Needham & Company Debanjana Chatterjee - JonesTrading Operator Good afternoon.

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance
prnewswire.com08 August 2024 Sentiment: POSITIVE

Topline results expected in the fourth quarter of 2024 in the Phase 2a RIVER trial in refractory chronic cough (RCC) Sample size re-estimation milestone is expected in the fourth quarter of 2024 in the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF) Ended the second quarter of 2024 with $69.5 million in cash, cash equivalents and marketable securities with expected cash runway into 2026 Management to host a conference call and webcast today at 4:30 p.m. ET  NEW HAVEN, Conn.

Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024
prnewswire.com01 August 2024 Sentiment: NEUTRAL

Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.

What type of business is Trevi Therapeutics?

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

What sector is Trevi Therapeutics in?

Trevi Therapeutics is in the Healthcare sector

What industry is Trevi Therapeutics in?

Trevi Therapeutics is in the Biotechnology industry

What country is Trevi Therapeutics from?

Trevi Therapeutics is headquartered in United States

When did Trevi Therapeutics go public?

Trevi Therapeutics initial public offering (IPO) was on 07 May 2019

What is Trevi Therapeutics website?

https://www.trevitherapeutics.com

Is Trevi Therapeutics in the S&P 500?

No, Trevi Therapeutics is not included in the S&P 500 index

Is Trevi Therapeutics in the NASDAQ 100?

No, Trevi Therapeutics is not included in the NASDAQ 100 index

Is Trevi Therapeutics in the Dow Jones?

No, Trevi Therapeutics is not included in the Dow Jones index

When was Trevi Therapeutics the previous earnings report?

No data

When does Trevi Therapeutics earnings report?

The next expected earnings date for Trevi Therapeutics is 20 March 2025